1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>Japan

Astellas Experiments With Partnering Models For a Phase IIa Ulcerative Colitis Compound

 
• By Daniel Poppy

Astellas out-licensed a melanocortin receptor agonist to a virtual company backed by Astellas' corporate venture arm.

TOKYO – Astellas Pharma Inc. has created what it calls a "uniquely structured partnership" in out-licensing a compound to Drais Pharmaceuticals Inc.,which in turn established a virtual company, Telsar Pharma, Inc., solely to develop the compound. Astellas hasn't washed its hands of the compound though; its corporate venture arm invested in the virtual company and retains a number of negotiation rights if the compound reaches proof-of-concept.

Astellas out-licensed ulcerative colitis therapy ASP3291, a melanocortin receptor agonist in the planning stages of a Phase IIa study, to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

PhRMA Urges Japan To Maintain Drug Prices Amid MFN Concerns

 
• By Lisa Takagi

While Japan tries to balance its healthcare costs, the major US industry group is concerned reimbursement pricing practices in the country could influence US levels under Trump's MFN policy.

Industry Excellence Celebrated At Citeline Japan Awards

 
• By Ian Haydock

Excellence, innovation and deal-making across the Japanese biopharma sector were celebrated at the Citeline Japan Awards 2025, held in Tokyo on 21 October.

US Confirms 15% Tariff On Japanese Drugs, But Confusion Lingers

 
• By Lisa Takagi

After tough negotiations which won the country a lower US levy on pharmaceuticals, there still appears to be some confusion within the Japanese government following President Trump's latest announcement on global pharma tariffs.

Publisher’s Spotlight: Shortlist Unveiled For Citeline Japan Awards

 
• By Ian Haydock

Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!

More from Asia

Where RWE Studies Stand In India And Bharat Serums’ Plans For The World’s Largest One

 
• By Vibha Ravi

Real-world evidence (RWE) studies in India face challenges like lack of data reliability and uniformity and absence of clear guidelines but firms like Bharat Serums have scored a regulatory win. Pink Sheet examines the RWE landscape and the BSV case study for lessons in beating the odds

China Eyes First-In-Class Blockbuster Drugs In Display of ‘Strategic Purpose’

A new 10-year, government-supported R&D program in China will focus on new targets and emerging technologies which can be translated into first-in-class drugs and give birth to top players in the global pharma industry.

Industry Excellence Celebrated At Citeline Japan Awards

 
• By Ian Haydock

Excellence, innovation and deal-making across the Japanese biopharma sector were celebrated at the Citeline Japan Awards 2025, held in Tokyo on 21 October.